

Rx Propellant unveils new research and innovation campus in Genome Valley

02 April 2025 | News

1GV is a beacon of modern life sciences infrastructure



Rx Propellant, India's premier life sciences infrastructure platform backed by Actis, has unveiled 1GV, a cutting-edge 136,000 sq. ft. research and innovation campus built over 1.8 acres in Genome Valley, Hyderabad. This launch marks another milestone in Rx Propellant's unwavering commitment to advancing India's life sciences ecosystem and shaping its future.

The story of 1GV is deeply intertwined with the origins of Genome Valley, one of Asia's largest life sciences clusters. This site, long before it became 1GV, was where the first brick was laid, setting the foundation for the region's remarkable growth.

Over the years, this campus has been instrumental in scientific breakthroughs, witnessing and contributing to the evolution of India's pharmaceutical, biotech, and contract research industries. This campus is a continuation of the legacy of the evolution of the Indian pharmaceutical and biotech industry, as 1GV is built on the historical grounds of the first construction in Genome Valley.

1GV is a beacon of modern life sciences infrastructure, designed to integrate sustainability at its core. With LEED Platinum & IFC EDGE Advanced Pre-Certification, the campus reflects a commitment to environmentally responsible development. Its world-class facilities are built for adaptability, scalability, and long-term growth, providing an optimal environment for life sciences enterprises. Beyond infrastructure, 1GV offers a suite of collaborative spaces designed to enhance connectivity, comfort, and well-being.

"The launch of 1GV marks a significant expansion of Rx Propellant's owned portfolio, now totaling three campuses, and reinforces our leadership in India's life sciences infrastructure. This strategic addition in Genome Valley, a key hub, strengthens our presence in Hyderabad and contributes to our broader pan-India vision of providing cutting-edge, sustainable infrastructure to support the sector's growth," said Milind Ravi, CEO of Rx Propellant.